By Counterforce Health Team in Amondys 45 (casimersen) —

How to Get Amondys 45 (Casimersen) Covered by Cigna in Ohio: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Amondys 45 Covered by Cigna in Ohio

Cigna requires prior authorization for Amondys 45 (casimersen) with strict eligibility criteria: genetic confirmation of exon 45-amenable DMD mutation, age under 14 at start, 6-minute walk test ≥300 meters, and specialist prescription. Submit through CoverMyMeds or Cigna provider portal with CLIA-certified genetic testing, baseline labs (cystatin C, creatinine, urinalysis), and pulmonary function tests. Standard review takes 72 hours to 5-10 business days. If denied, file internal appeal within 180 days, then request external review through Ohio Department of Insurance. Start today: Contact your neurologist to gather genetic testing results and schedule baseline assessments.

Table of Contents

  1. Cigna's Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Prior Authorization Process
  4. Common Denial Reasons & Solutions
  5. Appeals Process in Ohio
  6. Clinical Monitoring Requirements
  7. Costs and Financial Assistance
  8. Frequently Asked Questions
  9. Sources & Further Reading

Cigna's Coverage Policy Overview

Cigna classifies Amondys 45 (casimersen) as a specialty medication requiring prior authorization across all plan types—HMO, PPO, and Medicare Advantage. The drug is typically managed through Express Scripts/Accredo specialty pharmacy networks.

Key Policy Points:

  • Prior authorization required for all new starts and renewals
  • Genetic testing confirmation mandatory
  • Age restrictions apply (under 14 at treatment initiation)
  • Specialist prescriber requirement (neurologist or neuromuscular specialist)
  • Regular monitoring and documentation needed for continuation

You can find Cigna's official coverage criteria in their Casimersen Coverage Position document.

Medical Necessity Requirements

Coverage at a Glance

Requirement What It Means Documentation Needed Source
Genetic Confirmation CLIA-certified lab report showing mutation amenable to exon 45 skipping Complete DMD gene analysis with deletion/duplication mapping Cigna Policy
Age Limit Under 14 years at treatment start Birth certificate or medical records FDA Label
Ambulatory Status 6-minute walk test ≥300 meters Recent functional assessment by qualified clinician Cigna Policy
Pulmonary Function Forced vital capacity ≥50% predicted Pulmonary function test results Cigna Policy
Specialist Care Neurologist or neuromuscular specialist prescription Provider credentials verification Cigna Policy

Baseline Laboratory Requirements

All laboratory values must be obtained within 30 days of prior authorization submission:

  • Renal function: Serum cystatin C and creatinine
  • Urinalysis: Including protein-to-creatinine ratio
  • Current weight: In kilograms for dosing calculations
  • Pulmonary function tests: FVC percentage predicted
Tip: The FDA label emphasizes that creatinine may be unreliable in DMD patients due to decreased muscle mass. Cystatin C provides a more accurate assessment of kidney function.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Gather Required Documentation (Patient/Family)
    • Insurance card and policy information
    • Complete genetic testing report from CLIA-certified lab
    • Recent clinic notes from neurologist
    • Functional assessment results (6MWT, pulmonary function)
  2. Schedule Baseline Assessments (Clinic)
    • Order labs: cystatin C, creatinine, urinalysis with UPCR
    • Perform or update pulmonary function tests
    • Document current weight and ambulatory status
  3. Submit Prior Authorization (Prescriber)
    • Use CoverMyMeds platform (preferred)
    • Alternative: Cigna provider portal or fax submission
    • Include all required documentation and clinical rationale
  4. Track Review Timeline (Patient/Clinic)
    • Standard review: 72 hours to 10 business days
    • Expedited review: 24-72 hours (if urgent medical need)
    • Contact Cigna Customer Service for status updates
  5. Coordinate Specialty Pharmacy (Upon Approval)
    • Cigna typically routes to Express Scripts/Accredo
    • Confirm infusion site meets plan requirements
    • Schedule initial treatment and ongoing monitoring

Submission Channels

Electronic (Preferred):

  • CoverMyMeds portal for fastest processing
  • Cigna provider portal (login required)

Traditional Methods:

  • Fax: Use plan-specific prior authorization forms
  • Phone: Cigna Customer Service number on member ID card

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
Missing genetic confirmation Submit CLIA-certified genetic report explicitly stating "amenable to exon 45 skipping" Complete DMD gene analysis with interpretation
Age over 14 at start Provide birth certificate and treatment timeline Official age verification documents
Insufficient ambulatory function Submit recent 6MWT results showing ≥300 meters Formal functional assessment by qualified clinician
Non-specialist prescriber Transfer prescription to neurologist or neuromuscular specialist Provider credentials and specialty board certification
Missing baseline labs Complete required testing within 30 days of resubmission Cystatin C, creatinine, urinalysis with UPCR

Medical Necessity Letter Checklist

Your prescriber's letter should include:

  • Patient demographics: Age, weight, DMD diagnosis with ICD-10 code
  • Genetic confirmation: Specific mutation and exon 45 skipping amenability
  • Clinical status: Current functional abilities, disease progression
  • Prior treatments: Corticosteroids, other DMD therapies tried
  • Treatment rationale: Why Amondys 45 is medically necessary now
  • Monitoring plan: Renal function, pulmonary assessments, efficacy measures

Appeals Process in Ohio

Internal Appeals with Cigna

First-Level Internal Appeal:

  • Deadline: 180 days from denial notice
  • Who can file: Patient, authorized representative, or prescriber
  • How to submit: Written appeal via mail, fax, or online portal
  • Timeline: Standard review within 30 days, expedited within 72 hours

Second-Level Internal Appeal:

  • Available if first-level appeal is denied
  • Same submission process and timelines apply
  • Must exhaust internal appeals before external review

External Review Through Ohio Department of Insurance

If Cigna upholds the denial after internal appeals, Ohio residents can request an independent external review.

Key Details:

  • Deadline: 180 days from final internal denial
  • Cost: Free to patient
  • Process: Random assignment to qualified Independent Review Organization (IRO)
  • Timeline: 30 days for standard review, 72 hours for expedited
  • Decision: Binding on Cigna if overturned

How to Request:

  1. Contact Ohio Department of Insurance at 1-800-686-1526
  2. Submit external review request form
  3. Include all relevant medical records and correspondence
  4. IRO will review case independently of Cigna
Note: Self-funded employer plans may follow federal ERISA rules instead of Ohio's external review process. Check with your HR department to confirm your plan type.

Clinical Monitoring Requirements

FDA-Required Safety Monitoring

Kidney Function (Primary Safety Concern):

  • Before starting: Serum cystatin C, urine dipstick, protein-to-creatinine ratio
  • During treatment: Monthly urine dipstick, quarterly cystatin C and UPCR
  • Important: Collect urine samples before infusion or ≥48 hours after to avoid drug interference

Infusion Protocol:

  • Weekly IV infusions at 30 mg/kg body weight
  • Administered over 35-60 minutes
  • 0.2 micron in-line filter required
  • Flush line with normal saline before and after

Continuation Requirements

Cigna requires periodic documentation of:

  • Functional assessments: 6-minute walk test, motor function measures
  • Pulmonary function: FVC percentage, respiratory status
  • Treatment adherence: Infusion attendance, monitoring compliance
  • Clinical benefit: Stability or improvement from baseline

Costs and Financial Assistance

Insurance Coverage

With Cigna approval, Amondys 45 is typically covered as a specialty medication with higher copays or coinsurance. Your out-of-pocket costs depend on your specific plan's specialty drug benefits.

Financial Assistance Options

  • Sarepta Therapeutics Patient Support: Contact manufacturer for copay assistance programs
  • Foundation grants: Organizations like Patient Advocate Foundation may provide assistance
  • State programs: Ohio may have additional rare disease support resources
Tip: Start financial assistance applications early, as processing can take several weeks.

How Counterforce Health Can Help

Counterforce Health specializes in turning insurance denials into successful appeals for specialty medications like Amondys 45. Our platform analyzes denial letters, identifies the specific coverage criteria, and drafts evidence-backed appeals that address each payer's requirements. We help patients, clinicians, and specialty pharmacies navigate complex prior authorization processes and appeal denials with targeted, policy-specific rebuttals.

For families dealing with DMD and insurance challenges, having expert support can make the difference between a successful appeal and continued treatment delays. Counterforce Health provides the specialized knowledge needed to advocate effectively with payers like Cigna.

Frequently Asked Questions

How long does Cigna prior authorization take for Amondys 45 in Ohio? Standard review takes 72 hours to 10 business days. Expedited review (for urgent medical situations) is completed within 24-72 hours.

What if Amondys 45 is not on Cigna's formulary? You can request a formulary exception through Cigna's standard process. Your prescriber must demonstrate medical necessity and provide clinical justification for why formulary alternatives are inappropriate.

Can I get an expedited appeal if my child needs treatment urgently? Yes, if a delay would seriously jeopardize your child's health, you can request expedited internal appeals (72 hours) and expedited external review (72 hours) in Ohio.

Does step therapy apply if we've tried other DMD treatments? Cigna may require documentation of prior corticosteroid therapy, but there are no direct alternatives to exon 45 skipping therapy. Previous failures with other DMD treatments can support medical necessity.

What happens if our genetic testing is from an out-of-state lab? As long as the lab is CLIA-certified and the report clearly states the mutation is amenable to exon 45 skipping, out-of-state testing should be acceptable.

How often do we need to renew prior authorization? Cigna typically requires annual renewal with updated functional assessments, lab results, and clinical documentation of continued benefit.

Can we appeal if our child turns 14 during treatment? Yes, the age requirement applies to treatment initiation. Once approved and started before age 14, treatment can continue with proper monitoring and documentation of benefit.

What if Express Scripts/Accredo isn't available in our area? Contact Cigna Customer Service to discuss alternative specialty pharmacy options that meet their network requirements and can provide proper infusion coordination.

From our advocates: We've seen families successfully appeal initial Amondys 45 denials by ensuring their genetic testing report explicitly states "amenable to exon 45 skipping" rather than just listing the mutation. This specific language alignment with Cigna's policy criteria often makes the difference in approval decisions.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and requirements may change. Always verify current requirements with Cigna and consult with your healthcare team for medical decisions. For personalized assistance with insurance appeals and prior authorization, consider consulting with healthcare advocates or organizations like Counterforce Health that specialize in payer communications.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.